Halobetasol 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis of the Lower Extremities

Neal Bhatia; Tracey C Vlahovic; Lawrence Green; Gina Martin; Tina Lin

doi:10.25251/skin.3.supp.32

Neal Bhatia

Therapeutics Clinical Research, San Diego, CA

Tracey C Vlahovic

Temple University School of Podiatric Medicine, Philadelphia, PA

Lawrence Green

Department of Dermatology, George Washington University School of Medicine, Washington, DC

Gina Martin

Bausch Health Americas, Inc., Petaluma, CA

Tina Lin

Ortho Dermatologics, Bridgewater, NJ

Keywords

psoriasis, halobetasol

Abstract

Abstract not available.

References

1. Nestle FO, et al. N Engl J Med. 2009;361(5):496-509.

2. Lam LH and Sugarman JL. J Drugs Dermatol. 2016;15(8):945-948.

3. Blauvet A, et al. J Dermatolog Treat. 2018;29(3):220-229.

4. Armstrong AW, et al. Am J Clin Dermatol. 2016;17:691-699.

5. Sugarman JL, et al. Cutis. 2019;103(2):11-116.

6. Green LJ, et al. J Drugs Dermatol. 2018;17(10):1062-1069.

7. Bernhard J, et al. J Am Acad Dermatol. 1991;25:1170-1174.

Poster PDF

Published

Nov 9, 2019

DOI https://doi.org/10.25251/skin.3.supp.32

How to Cite

[1]

Bhatia, N., Vlahovic, T.C., Green, L., Martin, G. and Lin, T. 2019. Halobetasol 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis of the Lower Extremities. SKIN The Journal of Cutaneous Medicine. 3, (Nov. 2019), S32. DOI:https://doi.org/10.25251/skin.3.supp.32.

Issue

Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas

Section

Poster Presentations from FC23 Dermatology Conference®: Psoriasis

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

Joseph Merola, Milan Anadkat, Neal Bhatia, Tina Bhutani, Laura Ferris, Arash Mostaghimi, .Jason Guercio, Christian Thoma, Ming Tang, Mark Lebwohl, Spesolimab Use for Generalized Pustular Psoriasis Flare Prevention in Patients with Concomitant Plaque Psoriasis: Results from the Effisayil 2 Trial , SKIN The Journal of Cutaneous Medicine: Vol. 8 No. 2 (2024): March 2024 Issue
Todd Schlesinger, Leon Kircik, James Del Rosso, Darrell Rigel, Mark Lebwohl, Brian Berman, April Armstrong, Neal Bhatia, Vishal A. Patel, Siva Narayanan, Volker Koscielny, Ismail Kasujee, Clinician- and Patient-Reported Outcomes with Tirbanibulin 1% Treatment for Actinic Keratosis in Routine Clinical Practice Across the U.S. (PROAK Study) , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 3 (2023): May Issue and Posters from WCH23 & WCM23
Mark Lebwohl, Leon Kircik, Angela Moore, Linda Stein Gold, James Del Rosso, Zoe Draelos, Melinda Gooderham, Lawrence Green, Adelaide Herbert, Kim Papp, Jerry Bagel, Neal Bhatia, Laura Ferris, Terry Jones, Steve Kempers, David Pariser, Paul Yamauchi, Matthew Zirwas, Amy Feng, Patrick Burnett, Robert Higham, David Berk, Once-Daily Roflumilast Cream 0.3%, a Potent Phosphodiesterase-4 Inhibitor, Provided Safe and Effective Treatment of Psoriasis in the DERMIS-1 and DERMIS-2 Phase 3 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Justin Marson, James Del Rosso, Neal Bhatia, Darrell Rigel, Considerations in the Management of Actinic Keratosis: The Importance of Adherence and Persistence to Therapy , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 2 (2021)
Melinda J. Gooderham, Leon H. Kircik, Matthew Zirwas, Mark Lee, Steven E. Kempers, Zoe D. Draelos, Laura Ferris, Terry M. Jones, Etienne Saint-Cyr Proulx, Robert Bissonnette, Neal Bhatia, Scott T. Guenthner, Robert A. Koppel, Howard Welgus, Charlotte Merritt, Meg Elias, Lynn Navale, Robert C. Higham, Michael Droege, David R. Berk, The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Atopic Dermatitis: Phase 2 Proof-of-Concept Study , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Brian Berman, April Armstrong , Mark Lebwohl, Ayman Grada, Neal Bhatia, Vishal Patel, Darrell Rigel, James Del Rosso, Todd Schlesinger, Leon Kircik, Raidah Salem, Ismail Kasujee, Patient-Reported Outcomes for Tirbanibulin Effectiveness and Safety in Actinic Keratosis in Real-world Settings: PROAK Study Protocol , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Andrew Blauvelt, Javier Alonso-Llamazares, Neal Bhatia, Zoe Draelos, Janet DuBois, Seth Forman, Melinda Gooderham, Scott Guenthner, Adelaide Hebert, Edward Lain, Angela Moore, Kim Papp, Linda Stein Gold, Matthew Zirwas, Saori Kato, Scott Snyder, David Krupa, Patrick Burnett, David Berk, David Chu, Efficacy and Safety of Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis in a Phase 3 Trial , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Linda Stein Gold, Mark Lebwohl, Neal Bhatia, Douglas DiRuggiero, Abby Jacobson, Radhakrishnan Pillai, Long-Term Management of Moderate-to-Severe Plaque Psoriasis: Maintenance of Treatment Success Following Cessation of Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Linda Stein Gold, Andrew Blauvelt, April Armstrong , Seemal Desai, Howard Sofen, Lawrence Green, Steve Tyring, Laura Ferris, Philip Brown, David Rubenstein, Stephen Piscitelli, Anna Tallman, Leon Kircik, Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Secondary Efficacy Outcomes from Two Pivotal Phase 3 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Todd Schlesinger, Neal Bhatia, Brian Berman, Ayman Grada, Albert Torra, David Cutler, Mark Lebwohl, Favorable Safety Profile of Tirbanibulin Ointment 1% for Actinic Keratosis: Pooled Results from Two Phase III Studies , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)

1 2 3 4 5 6 7 8 9 > >>

Main Article Content

Keywords

Abstract

References

Article Sidebar

Article Details

Similar Articles

Most read articles by the same author(s)